Shilpa Medicare Ltd (SHILPAMED)
₹935.45
Mkt cap
₹18,857 Cr
P/E ratio
66.30
P/B
7.09
Div yield
0.06%
ROE
8.99%
ROCE
10.90%
EPS (TTM)
₹14.11
Book value
₹132
52W range
267–958
Sector
Healthcare
Price history
Previous close
Shilpa Medicare Incorporated in 1987 manufactures niche APIs, intermediates, and formulations and also undertakes contract research and manufacturing service for some of its customers. The company’s formulation products consist of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SML’s wholly owned subsidiary Shilpa Therapeutics. [1]
NSE SHILPAMEDBSE 530549
Health check
Mixed
ValuationExpensive
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
−2.35% from high₹935
₹267+250.36% from low₹958
Current
₹935.45
Prev close
₹958.00
Day
−2.35%
Price performance
1D
−2.35%
1W
−1.46%
1M
+23.13%
3M
+64.36%
6M
+196.31%
1Y
+119.99%
YTD
+192.51%
Financials
Revenue, profit & margin
P/E ratio
66.3×
SHILPAMED is 95% above the sector median of 34.0×
SHILPAMED66.3×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 260 | 313 | 287 | 292 | 293 | 344 | 319 | 331 | 321 | 370 | 410 | 437 | 466 | |
| Expenses | 214 | 255 | 222 | 222 | 222 | 258 | 239 | 252 | 231 | 262 | 296 | 317 | 330 | |
| Operating Profit | 46 | 58 | 65 | 70 | 70 | 86 | 81 | 79 | 91 | 108 | 114 | 120 | 136 | |
| OPM % | 18% | 19% | 23% | 24% | 24% | 25% | 25% | 24% | 28% | 29% | 28% | 27% | 29% | |
| Other Income | 2 | 2 | 2 | 9 | 10 | 5 | 2 | -21 | 6 | 2 | -13 | 45 | 9 | |
| Interest | 18 | 23 | 26 | 24 | 24 | 26 | 12 | 14 | 19 | 16 | 11 | 14 | 12 | |
| Depreciation | 27 | 28 | 27 | 27 | 27 | 28 | 29 | 29 | 29 | 30 | 30 | 31 | 35 | |
| Profit before tax | 3 | 9 | 14 | 28 | 29 | 37 | 42 | 15 | 50 | 64 | 61 | 120 | 98 | |
| Tax % | 64% | 83% | 67% | 12% | 51% | 51% | 24% | 5% | 5% | 32% | 27% | 10% | -3% | |
| Net Profit | 1 | 2 | 5 | 24 | 14 | 18 | 32 | 15 | 47 | 44 | 45 | 108 | 101 | |
| EPS in Rs | 0.07 | 0.09 | 0.26 | 1.41 | 0.72 | 0.92 | 1.62 | 0.74 | 2.40 | 2.25 | 2.28 | 5.51 | 5.16 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +11.96% · closed higher next day 1 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 5 Aug '26 |
| Earnings day | +11.96% |
| +1 day | +14.60% |
| +5 days | +24.90% |
| +15 days | +33.52% |
| +30 days | — |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202640.13%Promoter
Promoters40.13%
FIIs11.39%0.32
DIIs8.05%0.53
Public40.42%0.21
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| SHILPAMED | ₹964.15 | 66.32 | 18,857 | 0.06% | 101 | +115.14% | 466 | +44.90% | 10.88% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013nseAnnual Report 2013bse
Concall transcripts57
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024TranscriptJul 2024
Credit ratings6
Announcements5
Dispatch Of Letter To Shareholders Whose E-Mail Addresses Are Not Registered With Company/Registrar & Transfer Agent /Depository Participants 19 Aug - 39th AGM on 11 September 2026; annual report and e-voting details shared.Response On The News Item Captioned 'Shilpa Medicare Recalls Over 27K Vials Of Chemotherapy Drug In US' Published In The Online Edition Of The Economic Times On August 17, 2026 - Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015. 18 Aug - Shilpa Medicare voluntarily recalled 27,923 Pemetrexed vials in the US on July 29, 2026; Class II recall.Announcement under Regulation 30 (LODR)-Dividend Updates 17 Aug - Sharesholder notice on TDS for final dividend of Re.0.60; record date 4 Sept 2026, AGM 11 Sept 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 14 AugReg. 34 (1) Annual Report. 13 Aug